Madrigal Pharmaceuticals Inc (NAS:MDGL)
$ 318.55 -9.64 (-2.94%) Market Cap: 6.95 Bil Enterprise Value: 6.28 Bil PE Ratio: 0 PB Ratio: 8.94 GF Score: 42/100

Madrigal Pharmaceuticals Inc at JMP Securities Life Sciences Conference Transcript

May 16, 2023 / 02:30PM GMT
Release Date Price: $292.21 (+0.66%)
Unidentified Analyst

Good morning, everybody, and thanks for joining day two of the JMP Life Science Conference. My name is John Walden. I'm pleased to have the team from Madrigal Pharmaceuticals joining us Rebecca Taub, CMO; CEO, Paul Friedman; and Chief Commercial Officer, Remy Sukhija. Thanks for joining us today, guys. I think everybody is familiar with the Madrigal story by now and the unmet need in NASH. But maybe to start, can we talk about the master of NASH data and the key learnings and then what that means moving forward for you guys?

Rebecca Taub
Madrigal Pharmaceuticals, Inc. - Director, Founder, Chief Medical Officer and President of Research & Development

Yeah. So as you know, we announced data the December of 42, and we have an update in January of 23 where we achieve both liver biopsy primary endpoints of the study, which was it's a 54-month study in overall, but there was a 52-week serial liver biopsy endpoint and about 1,000 patients. And we showed that resmetirom had both daily doses, 80 and 100 milligrams achieved the primary endpoints which

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot